Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction

European Respiratory Journal

Volumn 21, Issue 1, 2003, Pages 19-24

  Hubloue, I ^a   Biarent, D ^a   Abdel Kafi, S ^a   Bejjani, G ^a   Kerbaul, F ^a   Naeije, R ^a   Leeman, M ^b  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Endothelins; Hypoxic pulmonary vasoconstriction; Nitric oxide; Pulmonary hypertension

Indexed keywords

BOSENTAN; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOG; ENZYME INHIBITION; HYPOXIA; HYPOXIC LUNG VASOCONSTRICTION; IN VIVO STUDY; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG CIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING;

EID: 0037249512     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00025403a     Document Type: Article

References (36)

1. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med 1996; 154: 555-581.
2. Taddei S, Virdis A, Ghiadoni L, Sudano I, Notari M, Salvetti A. Vasoconstriction to endogenous endothelin-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation 1999; 100: 1680-1683.
3. Verhaar MC, Strachan FE, Newby DE, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin B receptor blockade. Circulation 1998; 97: 752-756.
4. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V, for the Bosentan Hypertension Investigators. The effects of endothelin-receptor antagonist, bosentan, on blood pressure in patients with arterial hypertension. N Engl J Med 1998; 338: 784-790.
5. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
6. Channick RN, Simmoneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
7. Teerlink JR, Carteaux JP, Sprecher U, Löffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 1995; 268: H432-H440.
8. Sato K, Morio Y, Morris KG, Rodman DM, McMurtry IF. Mechanism of hypoxic pulmonary vasoconstriction involves endothelin A receptor-mediated inhibition of KATP channel. Am J Physiol 2000; 278: L434-L442.
9. Holm P, Liska J, Franco-Cereceda A. The endothelin A receptor antagonist, BMS-182874, reduces acute hypoxic pulmonary hypertension in pigs in vivo. Cardiovasc Res 1998; 37: 765-771.
10. Willette RN, Ohlstein EH, Mitchell MP, et al. Nonpeptide endothelin receptor antagonists. VIII: attenuation of acute hypoxia-induced pulmonary hypertension in the dog. J Pharmacol Exp Ther 1997; 280: 695-701.
11. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995; 79: 2122-2131.
12. Oparil S, Chen SJ, Meng QC, Elton TS, Yano M, Chen YF. Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat. Am J Physiol 1995; 268: L95-L100.
13. Wang Y, Coe Y, Toyoda O, Coceani F. Involvement of endothelin-1 in hypoxic pulmonary vasoconstriction in the lamb. J Physiol 1995; 482: 421-434.
14. Bonvallet ST, Zamora MR, Hasunuma K, et al. BQ123, an ETA-receptor antagonist, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1994; 266: H1327-H1331.
15. Wong J, Vanderford PA, Winters JW, Chang R, Soifer SJ, Fineman JR. Endothelin-1 does not mediate acute hypoxic pulmonary vasoconstriction in the intact newborn lamb. J Cardiovasc Pharmacol 1993; 22: S262-S266.
16. Banting JD, Friberg P, Adams MA. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens 1996; 14: 975-981.
17. Richard V, Hogie M, Clozel M, Löffler BM, Thuillez C. In vivo evidence of an endothelin-induced vasopressor tone after inhibition of nitric oxide synthesis in rats. Circulation 1995; 91: 771-775.
18. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993; 92: 99-104.
19. Muramatsu M, Rodman DM, Oka M, McMurtry IF, Endothelin-1 mediates nitro-L-arginine vasoconstriction of hypertensive rat lungs. Am J Physiol 1997; 272: L807-L812.
20. Elton TS, Oparil S, Taylor GR, et al. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am J Physiol 1992; 263: R1260-R1264.
21. Lazor R, Feihl F, Waeber B, Kucera P, Perret C. Endothelin-1 does not mediate the endothelium-dependent hypoxic contractions of small pulmonary arteries in rats. Chest 1996; 110: 189-197.
22. Takeoka M, Ishizaki T, Sakai A, et al. Effects of BQ-123 on vasoconstriction as a result of either hypoxia or endothelin-1 in perfused rat lungs. Acta Physiol Scand 1995; 155: 53-60.
23. Douglas SA, Vickery-Clark LM, Ohlstein EH. Endothelin-1 does not mediate hypoxic vasoconstriction in canine isolated blood vessels: effect of BQ-123. Br J Pharmacol 1993; 108: 418-421.
24. Leeman M, Zegers de Beyl V, Biarent D, Maggiorini M, Mélot C, Naeije R. Inhibition of cyclooxygenase and nitric oxide synthase in hypoxic vasoconstriction and oleic acid-induced lung injury. Am J Respir Crit Care Med 1999; 159: 1383-1390.
25. Leeman M, Zegers de Beyl V, Delcroix M, Naeije R. Effects of endogenous nitric oxide on pulmonary vascular tone in intact dogs. Am J Physiol 1994; 266: H2343-H2347.
26. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-235.
27. Gabbay E, Fischer AJ, Small T, Leonard AJ, Corris PA. Exhaled single-breath nitric oxide measurements are reproducible, repeatable and reflect levels of nitric oxide found in the lower airways. Eur Respir J 1998; 11: 467-472.
28. Winer BJ. Statistical Principles in Experimental Design. New York, McGraw-Hill, 1991.
29. Thebaud B, de Lagausie P, Forgues D, Aigrain Y, Mercier JC, Dinh-Xuan AT. Endothelin A receptor blockade and endothelin B receptor stimulation in experimental congenital diaphragmatic hernia. Am J Physiol 2000; 278: L923-L932.
30. Ovadia B, Bekker JM, Fitzgerald RK, et al. Nitric oxide-endothelin-1 interactions after acute ductal constriction in fetal lambs. Am J Physiol 2002; 282: H862-H871.
31. Ivy D, McMurtry IF, Yanagisawa M, et al. Endothelin B receptor deficiency potentiates endothelin-1 and hypoxic pulmonary vasoconstriction. Am J Physiol 2001; 280: L1040-L1048.
32. Sato K, Rodman DM, McMurtry IF. Hypoxia inhibits increased endothelin B receptor-mediated NO synthesis in hypertensive rat lungs. Am J Physiol 1999; 276: L571-L581.
33. Fujii Y, Magder S, Cernacek P, Goldberg P, Guo Y, Hussain SNA. Endothelin receptor blockade attenuates lipopolysaccharide-induced pulmonary nitric oxide production. Am J Respir Crit Care Med 2000; 161: 982-989.
34. Leeman M, Zegers de Beyl V, Gilbert E, Mélot C, Naeije R. Is nitric oxide released in oleic acid lung injury? J Appl Physiol 1993; 74: 650-654.
35. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333: 214-221.
36. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328: 1732-1739.